clinical trial · NCT06073847
A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis
Bristol-Myers Squibb·—·recruiting·n = 137
Primary MyelofibrosisPost-polycythemia Vera MyelofibrosisPost-essential Thrombocythemia MyelofibrosisFedratinib
brief summary
The purpose of this study is to assess the real-world safety of fedratinib for the treatment of adult participants with primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), or post essential thrombocythemia myelofibrosis (post-ET MF) who were previously treated with ruxolitinib. Participants will represent the overall patient population with PMF, post-PV MF or post-ET MF who lost adequate response to and/or are intolerant to ruxolitinib. Inadequate response definitions will follow Ministry of Food and Drug Safety-approved label and reimbursement criteria of the Health Insurance Review \& Assessment Service.
started
Jun 13, 2023
primary completion
Dec 20, 2027
completion
Dec 20, 2027
last updated
Nov 6, 2024
official title
Inrebic® (Fedratinib) Post-Marketing Surveillance in Korean Patients With Myelofibrosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol